



Cambridge
International

Professional Research Thesis

Titled

The role of managing personal awareness in using the
umbilical cord and in developing medical treatments
and healing diseases

Researcher

Riham Mohamed Raouf Hasan Askar

Supervisor signature

2024



SUMMARY

Stem cells are a fundamental element in cell transformation, regeneration, and natural healing. In the realm of medicine and health sciences, recent advancements in therapies and medical research present significant challenges that need to be addressed. Among the research topics that capture the interest of researchers and medical professionals is the use of umbilical cord blood in treatment, which is of particular importance. Understanding how to benefit from this valuable biological resource in therapy opens new horizons for medical treatment and interventions.

This paper presents a comprehensive study on this complex subject. We will explore the potential effects of using umbilical cord blood to treat a variety of diseases, discuss the expected outcomes, and address the challenges associated with this therapeutic approach. The paper will rely on recent research and scientific evidence to understand how to apply this technique efficiently and effectively. The aim is to make a valuable contribution to the field of medicine and guide recent developments toward improving patient care and providing more effective and safe treatments.

These regenerative properties play a central role in modern disease treatment. Stem cells are natural pharmacies typically found in bone marrow, adipose tissue, dental pulp, or peripheral blood of all people and are responsible for the growth of healthy cells and tissues. When a stem cell divides, the new cell has the option to either remain as is or differentiate into another type with a different function. This process is called differentiation.

Umbilical cord blood is the blood collected from the blood vessels of the placenta and umbilical cord after separation from both the newborn and the mother. Consequently, the injection of umbilical cord blood has been approved for use in stem cell transplantation to stimulate natural healing and regeneration. This is because umbilical cord blood contains stem cells that develop into blood cells. Therefore, it is extremely beneficial in treating a number of conditions related to blood disorders and the immune system, including joint damage, ligament and tendon damage, and degenerative joint disease.

Stem cell research has found that umbilical cord blood contains very high concentrations of hematopoietic stem cells, which eventually develop into blood-forming cells. These resulting stem cells are called hematopoietic stem cells or blood-forming stem cells, and they have been found to resemble bone marrow cells, which have been widely used to treat a variety of genetic disorders, blood diseases, and autoimmune diseases such as lupus and diabetes, as well as kidney diseases and post-cancer treatments.

Therefore, science and medicine hold much hope for the development of stem cell research and regenerative medicine. This research will define the concept of regenerative medicine and focus on the abundant source of stem cells from neonatal tissues such as the umbilical cord.

Umbilical cord blood has been clinically used for over 20 years as a source of cells for hematopoietic stem cell transplantation. Beyond that, umbilical cord blood and stem cells derived from it have shown potential for differentiation into various cell types (such as liver, pancreas, and neural tissues) both in the laboratory and in vivo. This promising research has ushered in a new era of using neonatal stem cells, which are now being

used outside the realm of blood diseases in clinical trials for autoimmune disorders, cerebral palsy, and type 1 diabetes.

The study Problem.

The use of umbilical cord blood in therapy is a topic of great interest and controversy in the medical field. This practice has faced challenges and issues related to efficacy, safety, and practicality. It is essential to study this issue to understand the viability of using umbilical cord blood in treatment and to identify key areas of focus.

For instance, regarding the effectiveness of treatment using umbilical cord blood, it is crucial to determine whether there is sufficient evidence supporting its efficacy in various medical conditions. Additionally, it is important to investigate the risks and complications associated with umbilical cord blood therapy and the potential side effects of its use. There should be a focus on understanding the techniques and guidelines for application, improving these techniques for umbilical cord blood use in therapy, and determining the best practices for its implementation.

Furthermore, it is necessary to be aware of the laws and ethics surrounding the use of umbilical cord blood in treatment and how to regulate it. Raising public awareness about the significance of umbilical cord blood—which is often discarded after birth despite its remarkable benefits for treating chronic and otherwise incurable conditions through traditional methods—is also crucial.

Thus, this issue requires a comprehensive study to gain a better understanding of the benefits and challenges associated with the use of umbilical cord blood in therapy and to contribute to the development of relevant medical practices.

The importance of studying:

The use of umbilical cord blood in therapy is a topic of significant interest in the medical field for the following reasons:

- 1. Utilization of Stem Cells. Umbilical cord blood contains stem cells with immense therapeutic potential. These cells can be used to treat a variety of diseases and disorders, such as blood disorders and cancers. Studying the use of this type of therapy opens new avenues for research into successful treatments for diseases that were previously considered difficult to treat.*
- 2. Reducing Risks. Stem cells derived from umbilical cord blood may offer a safer and more effective alternative compared to those obtained from bone marrow, with reduced risks of transplant rejection and tissue compatibility issues. Additionally, the procedures for collecting umbilical cord blood are relatively simple and require fewer skills compared to other surgical methods, which can help reduce treatment costs.*
- 3. Increasing Scientific Understanding. These studies contribute to a greater understanding of how stem cells function and their mechanisms of action, paving the way for the development of*

future therapies. They offer hope to patients with serious diseases who might find a chance for healing through this approach.

*4. **Rich Source of Stem Cells:** Umbilical cord blood contains large quantities of stem cells, which are valuable for treating chronic diseases such as cancer and blood disorders. Research into the use of these cells could open new doors for treatments, contributing to the development of innovative therapies for a range of conditions, including genetic and neurological disorders.*

*5. **Research and Development:** Studying this topic advances research and development in the fields of medicine and health sciences.*

Objectives of the study:

This study aims to achieve a set of primary objectives that enhance our understanding of the role and impact of using umbilical cord blood in therapy, and to guide towards a more advanced and improved future in healthcare.

The study seeks to achieve the following:

- 1. **Understanding Efficacy** : To evaluate the effectiveness of using umbilical cord blood in treating a variety of diseases, including chronic and genetic conditions, and to measure the success of this therapeutic approach.*
- 2. **Assessing Safety** : To assess the risks and safety of using umbilical cord blood in therapy, including addressing any potential complications or health issues.*
- 3. **Determining Optimal Techniques**: To explore the best techniques and methods for using umbilical cord blood in therapy, and to improve procedures to ensure the success of the treatment.*
- 4. **Analyzing Costs**: To estimate the financial costs and resources required for using umbilical cord blood in therapy and provide a comprehensive evaluation of the economic aspects.*
- 5. **Guiding Future Developments**. To offer recommendations and guidance for future research and development in the field of umbilical cord blood therapy.*
- 6. **Improving Patient Care**. To advance the provision of enhanced healthcare for patients by leveraging the benefits of using umbilical cord blood in therapy.*

These objectives aim to guide the research towards a deeper understanding and better applications of this promising therapeutic approach, and to improve the quality of healthcare.

Study hypotheses and questions.

Hypotheses:

1. **Efficacy Hypothesis:** Can umbilical cord blood be used effectively as a biological resource for treating diseases?
2. **Safety Hypothesis:** Can umbilical cord blood be used safely without serious health complications?
3. **Optimal Techniques Hypothesis:** What are the most effective techniques for using umbilical cord blood in therapy?
4. **Cost Hypothesis:** Can treatment using umbilical cord blood be provided at a reasonable cost?
5. **Impact on the Immune System Hypothesis:** Can umbilical cord blood be used to strengthen the immune system during treatment?

Research Questions:

1. What is the efficacy of using umbilical cord blood in treating specific diseases, such as cardiovascular diseases and genetic disorders?
2. Are there specific techniques for using umbilical cord blood in therapy, such as the use of stem cells derived from it?
3. What are the potential complications of using umbilical cord blood in therapy, and how can they be avoided?
4. Does the efficacy of using umbilical cord blood vary depending on the diseases and the patients' conditions?
5. What are the economic and ethical challenges associated with utilizing umbilical cord blood in therapy?

6. Can this therapeutic approach be directed towards improving patient care and increasing their chances of recovery?

These are some of the important hypotheses and research questions concerning the use of umbilical cord blood in therapy. This study aims to guide research towards a deeper understanding of the efficacy and safety of this therapeutic approach and how to enhance patient care through it.

Study Approach.

The descriptive-analytical method was used to explore "the role of umbilical cord blood in developing medical treatments and healing diseases."

The limits of the study:

Spatial boundaries: The Egyptian Arabic Republic .

Time limits: 2000-2024

Study plan:

The study plan will be organized as follows, consisting of several chapters, sections, and subsections, as well as a conclusion:

Chapter One: Theoretical Framework and Scientific Concepts

- **Section One.**
 - *Introduction to Understanding Umbilical Cord Blood and the Stem Cells Derived from It*
 1. *Concept of Stem Cells and Regenerative Medicine*
 2. *What Distinguishes Stem Cells from Ordinary Cells in the Body*
 3. *HLA Typing & Matching Theory*
 4. *The Beginnings of Discovery and Use of Stem Cells from Umbilical Cord Blood in Therapy*
 5. *Characteristics and Advantages of Stem Cells from Umbilical Cord Blood in Therapy*
- **Section Two.**
 - *Therapeutic Applications of Stem Cells Derived from Umbilical Cord Blood*

1. *Applications of Umbilical Cord Blood Stem Cells in Treating Cancers, Rare Blood Diseases, and Joint Disorders*
2. *Techniques for Collecting and Processing Umbilical Cord Blood*
3. *Stem Cell Banks*
4. *Processes for Storing Umbilical Cord Blood in Stem Cell Banks, including Freezing and Thawing*
5. *Global Annual Awareness Month for Umbilical Cord Blood*

Chapter Two: Advantages of Using Stem Cells Derived from Umbilical Cord Blood in Therapy

- *Section One:*

- *Sources of Stem Cells in the Human Body*

1. *Stem Cells Derived from Bone Marrow*
2. *Stem Cells Derived from Peripheral Blood*
3. *Stem Cells Derived from Umbilical Cord Blood*

- *Section Two:*

- *What Distinguishes the Use of Stem Cells Derived from Umbilical Cord Blood (UCB–Stem Cells) from Other Types of Stem Cell Sources in the Body*

Chapter Three: Challenges and Solutions in Using Stem Cells Derived from Umbilical Cord Blood in Therapy

- *Section One.*

- *General Challenges and Solutions*
 1. *Ethical Challenges and Solutions*
 2. *Technical Challenges and Solutions*
 3. *Financial Challenges and Solutions*

- *Section Two.*

- *Medical Challenges and Solutions*
 1. *Rejection of the Transplant and Lack of Response to Treatment*

Chapter Four: Advances in Regenerative Medicine for Addressing Current Treatment Issues

- *Section One.*

- *Advanced Techniques in Stem Cell Therapy*

1. Gene Editing

2. Stem Cell Differentiation

3. Artificial Organ Manufacturing

- *Section Two.*

- *Latest Innovations in Regenerative Medicine*

- 1. Chimeric Antigen Receptor T Cells (CAR-T Cells)*

- 2. Exosomes*

- 3. Organoids*

Chapter One: Theoretical Framework and Scientific Concepts

Section One: Introduction to Understanding Umbilical Cord Blood and the Stem Cells Derived from It

1. Concept of Stem Cells and Regenerative Medicine

Definition of Stem Cells:

Stem cells are a special type of cell in the body with the ability to differentiate into various types of other cells. This ability to differentiate makes them distinctive and valuable to scientists and doctors. Stem cells come in two main types:

- 1. Embryonic Stem Cells:*** *These are found in the embryo and have the potential to transform into any type of cell in the body. Their primary source is the embryo.*
- 2. Adult Stem Cells:*** *These are found in mature tissues and play a role in repairing and regenerating the surrounding tissues. They can be found in places such as bone marrow and the intestines.*

Regenerative Medicine:

Regenerative medicine is a medical field that utilizes stem cells and tissue regeneration techniques to treat diseases and improve health. This includes:

- 1. Organ Transplantation:*** *Stem cells are used to develop artificial organs for transplantation into the body to address issues with living organs.*

2. **Treatment of Chronic Diseases:** Stem cells can be used to treat chronic diseases such as diabetes and cancer.
3. **Tissue Regeneration:** Tissue regeneration is used to repair damaged tissues caused by injuries or diseases.
4. **Scientific Research:** Stem cells play a crucial role in biomedical research and medical advancements.

In summary, stem cells and regenerative medicine can open promising avenues for treating diseases and enhancing quality of life.

2. What Distinguishes Stem Cells from Ordinary Cells in the Body:

Stem cells are a remarkable technology in the medical field, offering extraordinary potential for treating diseases and improving quality of life. They possess exceptional abilities that set them apart from ordinary cells and open promising avenues for science and medicine.

Advantages of Stem Cells:

- ***Multipotent Differentiation:*** *Stem cells can transform into various types of cells, allowing for the repair of a diverse range of tissues and organs.*
- ***Regenerative Capability:*** *These cells continue to renew themselves for extended periods, making them an excellent source for long-term treatments.*
- ***Medical Uses:*** *Stem cells are used in multiple medical fields such as organ transplantation and chronic disease treatment.*

Differences Between Ordinary Cells and Stem Cells:

Ordinary Cells:

- ***Specific Function:*** *Ordinary cells are specialized to perform a specific function in the body, such as heart cells or liver cells.*
- ***Limited Regenerative Ability:*** *When damaged, ordinary cells can only replace themselves with the same type of cells.*

Stem Cells:

- ***Broader Differentiation:*** *Stem cells have the ability to differentiate into a wide range of different cells.*

- ***Greater Regenerative Capacity:*** *Stem cells continue to renew themselves for longer periods, which helps in maintaining tissue health.*

Section Two: What Distinguishes the Use of Stem Cells Derived from Umbilical Cord Blood

Using stem cells derived from umbilical cord blood has unique advantages that distinguish it from other sources of stem cells in the body:

- 1. **Ease of Collection:** The umbilical cord is a readily available source at birth, making the collection of stem cells possible without additional surgical procedures.*
- 2. **Lower Donor Risks:** In traditional transplantation procedures, there may be risks of the recipient's body rejecting the transplant. However, using umbilical cord blood cells from a matched source reduces the risk of rejection.*
- 3. **Differentiation Versatility:** Umbilical cord blood cells are capable of differentiating and developing into a wide range of tissues and organs, making them useful for treating various diseases.*
- 4. **Sustainable Storage:** Umbilical cord blood cells can be stored in private banks for extended periods, making them available for future use.*
- 5. **Effectiveness in Treating Certain Diseases:** Umbilical cord blood cells represent effective alternatives for treating diseases such as blood disorders, autoimmune diseases, and cancers.*

Overall, the use of stem cells from umbilical cord blood is considered a promising option for treating diseases due to its unique advantages and effectiveness in a variety of health conditions.

Conclusion.

In conclusion, it can be established that the umbilical cord plays a vital role in the development of medical treatments and contributes to the healing of diseases. By utilizing the stem cells found in the umbilical cord, innovative treatments can be developed for a variety of health conditions.

The research indicates that stem cells in the umbilical cord can aid in addressing chronic diseases, which are significant challenges in the field of medicine. Understanding the mechanisms and potential provided by the umbilical cord can open new avenues for research and innovation in the medical sciences.

Given the promising potential offered by the umbilical cord, further research and studies in this area should be supported to explore potential medical applications and enhance our understanding of how to maximize the benefits of this biological resource.

Results:

The role of the umbilical cord in developing medical treatments and healing diseases is a significant topic in medical research. Key findings include:

- 1. Umbilical Cord Contains Stem Cells: The umbilical cord contains hematopoietic stem cells, which can be used in developing treatments.*
- 2. Use of Stem Cells for Disease Treatment: Umbilical cord stem cells can be used to treat certain diseases, such as some types of cancer and anemia.*
- 3. Tissue Regeneration: Stem cells in the umbilical cord can be directed to regenerate and repair damaged tissues.*
- 4. Ongoing Research: There is ongoing research to explore other potential uses of the umbilical cord in developing new treatments.*
- 5. Benefits of Umbilical Cord Blood: In addition to stem cells, umbilical cord blood contains other components with medical benefits.*

Recommendations:

- **Basic Research:** Research should be directed towards understanding the role of the umbilical cord in tissue regeneration and enhancing healing processes.
- **Leveraging Technology:** Utilize advanced technology in analyzing and modifying stem cells from the umbilical cord to develop effective treatments.
- **Applied Research:** Direct research towards practical applications targeting specific areas of medicine and treatment.
- **International Collaboration:** Promote international collaboration in this field to exchange knowledge and technologies, and advance research progress.
- **Ethics:** Ensure all ethical principles are respected in the use of umbilical cord cells and the development of treatments.
- **Research Funding:** Direct investments in research and development towards this important area.
- **Public Awareness:** Raise public awareness about the importance of research into the role of the umbilical cord and the potential benefits of related medical treatments.
- **Use of Umbilical Cord Stem Cells:** It is recommended to use stem cells from the umbilical cord as a valuable source for medical treatments due to their ability to differentiate into various cell types and regenerate damaged tissues.

- ***Participation in Clinical Trials:*** *When reaching the clinical research phase, collaborate with research centers and hospitals to test the effectiveness of treatments.*

The reviewer:

1. Broxmeyer HE, Farag SS and R V. Thomas' hematopoietic cell transplantation. In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR, eds. *Thomas' Hematopoietic Cell Transplantation*. 5th ed.

UK: Oxford; 2019

2. Fuchs EJ, O'Donnell PV, Eapen M, et al. Double unrelated umbilical cord blood vs HLA-haploidentical bone marrow transplantation.

the BMT CTN 1101 trial. *Blood*. 2021

3. Strong A, Gračner T, Chen P, Kapinos K. On the value of the umbilical cord blood supply. *Value Heal*. 2018

4. Shearer WT, Lubin BH, Cairo MS, Notarangelo LD. Cord blood banking for potential future transplantation. *Obstet*

Gynecol Surv. 2018

5. States U, Accountability G. Report to congressional committees

National Cord Blood Inventory Practices for increasing availability

for transplants and related challenges practices for increasing availability

for transplants. 2011

6. Cohen S, Roy J, Lachance S, et al. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1–2 safety and feasibility study. Lancet Haematol. 2020

Haematol. 2020

7. Horwitz ME, Wease S, Blackwell B, et al. Phase I/II study of stem cell transplantation using a single cord blood unit expanded ex vivo with nicotinamide. J Clin Oncol. 2019

8. Horwitz ME, Stiff PJ, Cutler C, et al. Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study. Blood. 2021

9. Bonifazi F, Dan E, Labopin M, et al. Intrabone transplant provides full stemness of cord blood stem cells with fast hematopoietic recovery and low GVHD rate: results from a prospective study. Bone Marrow Transplant. 2019

10. Vairy S, Louis I, Vachon MF, et al. Intrabone infusion for allogeneic umbilical cord blood transplantation in children. Bone Marrow

Transplant. 2021

11. Xie G, Dong H, Liang Y, et al. CAR-NK cells: a promising cellular immunotherapy for cancer. EBioMedicine. 2020

12. Shimasaki N, Jain ACD. NK cells for cancer immunotherapy. Nat Rev Drug Discov. 2020

13. Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020

14. Tang X, Yang L, Li Z, et al. Erratum: First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 2018

15. Zhu H, Blum RH, Bjordahl R, et al. Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity. Blood. 2020

16. Strati P, Bachanova V, Goodman A, et al. Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK)

cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapse. J Clin Oncol.

2021

17. Kim HJ, Cho KR, Jang H, et al. Intracerebroventricular injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: a phase I clinical trial.

Alzheimer's Res Ther. 2021

18. Bartolucci J, Verdugo FJ, González PL, et al. Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2

randomized controlled trial (RIMECARD trial [Randomized

clinical trial of intravenous infusion umbilical cord mesenchymal.

Circ Res. 2017

19. Meng F, Xu R, Wang S, et al. Human umbilical cord-derived mesenchymal

stem cell therapy in patients with COVID-19: a phase

clinical trial. Signal Transduct Target Ther. 2020

20. Shu L, Niu C, Li R, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther. 2020

21. Passweg JR, Baldomero H, Bader P, et al. Hematopoietic stem cell transplantation in Europe 2014.

22. Kindwall-Keller TL, Ballen KK. Umbilical cord blood: the promise and the uncertainty. Stem Cells Translational Medicine. 2020.

23. Page KM, Labopin M, Ruggeri A, et al. Factors associated with long-term risk of relapse after unrelated cord blood transplantation in children with acute lymphoblastic leukemia in remission. Biol Blood Marrow Transplant. 2017.

24. Baron F, Ruggeri A, Beohou E, et al. Occurrence of graft-versus-host disease increases mortality after umbilical cord blood transplantation for acute myeloid leukaemia: a report from Eurocord and the ALWP of the EBMT. J Intern Med. 2018.

25. Yanada M, Konuma T, Kuwatsuka Y, et al. Unit selection for umbilical cord blood transplantation for adults with acute myeloid

leukemia in complete remission: a Japanese experience. Bone Marrow Transplant. 2019.

26. Fuchs EJ, O'Donnell PV, Eapen M, et al. Double unrelated umbilical cord blood versus HLA-haploidentical bone marrow transplantation (BMT CTN 1101). Blood. 2021.

27. Kindwall-Keller BKK. Umbilical cord blood: The promise and the uncertainty. Stem Cells Translational Medicine. 2020.

28. Milano F, Gooley T, Wood B, et al. Cord-blood transplantation in patients with minimal residual disease. N Engl J Med. 2016.

29. Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020.

30. Dave H, Luo M, Blaney JW, et al. Toward a rapid production of multivirus-specific T cells targeting BKV, adenovirus, CMV, and EBV from umbilical cord blood. Mol Ther Methods Clin Dev. 2017.

31. Kurtzberg J, Buntz S, Gentry T, et al. Preclinical characterization of DUOC-01, a cell therapy product derived from banked umbilical cord blood for use as an adjuvant to umbilical cord blood transplantation for treatment of inherited metabolic diseases. Cytotherapy. 2015.

32. Saha A, Patel S, Xu L, et al. Human umbilical cord blood monocytes, but not adult blood monocytes, rescue brain cells from hypoxic-ischemic injury: Mechanistic and therapeutic implications. *PLoS One*. 2019 .
33. Dawson G, Sun JM, Baker J, et al. A phase II randomized clinical trial of the safety and efficacy of intravenous umbilical cord blood infusion for treatment of children with autism spectrum disorder. *J Pediatr*. 2020 .
34. Sun JM, Dawson G, Franz L, et al. Infusion of human umbilical cord tissue mesenchymal stromal cells in children with autism spectrum disorder. *Stem Cells Translational Medicine*. 2020 .
35. Qu W, Wang Z, Hare JM, et al. Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome. *Stem Cells Translational Medicine*. 2020 .
36. Walker I, Panzarella T, Couban S et al. . Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haematopoietic cell transplantation from unrelated donors: A randomized, controlled, open-label, phase 3, multicentre trial. *Lancet Oncol* 2016 .

37. Jaiswal S, Fontanillas P, Flannick J et al. . Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J Med* 2014.
38. Ceberio I, Devlin SM, Sauter C et al. . Sirolimus, tacrolimus and low-dose methotrexate based graft-versus-host disease prophylaxis after non-ablative or reduced intensity conditioning in related and unrelated donor allogeneic hematopoietic cell transplant. *Leuk Lymphoma* 2015.
39. McCurdy SR, Kasamon YL, Kanakry CG et al. . Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. *Haematologica* 2017.
40. Oran B, Cao K, Saliba RM et al. . Better allele-level matching improves transplant-related mortality after double cord blood transplantation. *Haematologica* 2015.
41. D'Souza A, Fretham C. *Current Uses and Outcomes of Hematopoietic Cell Transplantation (HCT). CIBMTR Summary Slides, 2018.*
42. Gragert L, Eapen M, Williams E, et al. HLA match likelihoods for hematopoietic stem-cell grafts in the US registry. *N Engl J Med*. 2014.

43. Baron F, Ruggeria A, Beocous E, et al. Single- or double-unit UCBT following RIC in adults with AL: a report from Eurocord, the ALWP and the CTIWP of the EBMT. *J Hematol Oncol*. 2017.
44. Oran B, Cao K, Saliba RM, et al. Better allele-level matching improves transplant-related mortality after double cord blood transplantation. *Haematologica*. 2015.
45. Lazaryan A, Weisdorf DJ, Defor T, et al. Risk factors for acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation with umbilical cord blood and matched sibling donors. *Biol Blood Marrow Transplant*. 2016.